+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I trial of thermochemotherapy for brain malignancy



Phase I trial of thermochemotherapy for brain malignancy



Cancer 56(1): 48-56



High-grade primary and refractory brain tumors and metastases to the brain from other primary sites are associated with a grave prognosis. Treatment, usually palliative, consists of some combination of surgery, radiation, and chemotherapy. Recently, noninvasive hyperthermia by magnetic-loop induction has been safely used to treat patients with advanced cancer in extracranial sites. Both disease regression and disease stabilization have been observed. This technique was recently applied to brain tumors in an animal model, and its safety was again demonstrated. As a result, a Phase I trial of noninvasive localized hyperthermia in combination with intravenous chemotherapy has been carried out in ten patients whose primary or metastatic brain tumors failed to respond to standard therapy. Ten patients underwent 23 thermochemotherapy sessions using the magnetic-loop induction device. The median, maximum temperature of normal brain after 1 hour of hyperthermia was 41.1 degrees C (range, 38.6 degrees C-43.4 degrees C); the median, maximum temperature of brain tumor was 42.5 degrees C (range, 38.8 degrees C-46.3 degrees C) (P less than 0.01). The temperatures of both the normal brain and brain tumor were obtained during 18 treatments. The tumor temperature was greater than the normal brain temperature in 15 of 18 treatments. In 78% of the treatments, the measured tumor temperature reached at least 42 degrees C, whereas the normal brain reached 42 degrees C in only 13% of the treatments. These data demonstrate the "selective inability" of brain tumor tissue to dissipate heat. Vital signs, intracranial pressure, and neurologic status were monitored throughout the hyperthermia treatments. No mortality or increase in chemotherapeutic toxicity could be attributed to the thermochemotherapy. In addition, there were no local complications or permanent neurologic complications. Two patients with elevated intracranial pressure before therapy had transient neurologic deficits that may have been exacerbated by the hyperthermia. It is concluded that this new, noninvasive modality not only produced effective intracranial tumor heating, but could be performed safely with the proper precautions. Phase II trials are warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040963629

Download citation: RISBibTeXText

PMID: 4005792

DOI: 10.1002/1097-0142(19850701)56:1<48::aid-cncr2820560109>3.0.co;2-8


Related references

Sensitivity to thermochemotherapy of AKR lymphoma and B16 melanoma variants of malignancy. Clinical and Experimental Metastasis 8(1): 33-46, 1990

Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. Journal of Clinical Oncology 16(3): 1142-1149, 1998

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial. Translational Oncology 9(2): 108-113, 2016

Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer 112(5): 1083-1088, 2008

A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Japanese Journal of Clinical Oncology 36(4): 231-236, 2006

Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. Journal of Acquired Immune Deficiency Syndromes 72(1): 52-57, 2016

Phase I trial of imexon in patients with advanced malignancy. Journal of Clinical Oncology 25(13): 1779-1784, 2007

Phase i trial of dipyridamole dpm 5 fu and leukovorin lv in human malignancy. Clinical Pharmacology & Therapeutics 45(2): 136, 1989

5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy. Investigational new Drugs 2(4): 391-395, 1984

Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy. Journal of Clinical Oncology 13(9): 2238-2246, 1995

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of Oncology 19(11): 1969-1974, 2008

Phase i trial of 3 6 bis 2 piperidinoethoxyacridine cl 246738 in patients with advanced malignancy. Clinical Research 35(3): 525A, 1987

A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clinical Cancer Research 5(6): 1339-1345, 1999

Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Investigational new Drugs 23(3): 235-239, 2005